AbbVie completes acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Subscribe To Our Newsletter & Stay Updated